samedan logo
home > ebr > spring 2021 > the green shoots of tomorrow’s cell therapies
European Biopharmaceutical Review

The Green Shoots of Tomorrow’s Cell Therapies

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) defines a starting material as: “a raw material, intermediate, or an active pharmaceutical ingredient (API) that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement or produced in-house. API starting materials are normally of defined chemical properties and structure”. Cells are commonly used in biopharmaceutical manufacturing as a raw material and in the particular case of cell lines that serve as a starting point for cell therapies, that raw material itself becomes the API.

Induced pluripotent stem cells (iPSCs) are gaining traction as starting materials for a new generation of regenerative and immune cell therapies. Coaxed to a state that is indistinguishable from embryonic stem cells, iPSCs can be derived from ordinary cells of the body donated as biopsies or blood samples. Demonstrably pluripotent, iPSCs can potentially be differentiated into any cell type needed. Finally, with well-defined culturing, manipulation, and cryopreservation protocols, iPSC lines can be preserved indefinitely as an inexhaustible source of cellular material.

Whether generated at the hand of the therapy developer or purchased from a dedicated supplier, iPSCs destined for clinical applications are manufactured under certified Good Manufacturing Practice conditions and meet stringent quality criteria aimed at guaranteeing their safety for patients and comparability across cell lines. Perhaps less obvious than the advances that have pushed iPSCs toward clinical quality, are the ongoing efforts of therapy developers to explore the expansion options of allogeneic strategies. The concept of an ‘off-the-shelf’ starting material for cell therapies that are relevant for broad fractions of the human population and that may target multiple unmet indications is where the unique potential of iPSCs truly lies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Thomas Marx, Chief Commercial Officer, has over 25 years of global commercial management and leadership experience within the biopharmaceutical industry where he gained an in-depth understanding of the scientific and regulatory environment of product and therapy development. Thomas currently leads business development strategies and partnership management at RheinCell Therapeutics GmbH.

Dr Boris Greber, Chief Scientific Officer, heads the cell production and R&D activities at RheinCell Therapeutics GmbH. Prior to this role, Boris served as an independent research group leader at the Max Planck Institute for Molecular Biomedicine. He is an internationally recognised scientist with a 15-year track record in basic and applied human iPSC research.
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services


With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement